ARCHIVES

Study Of Tamoxifen And Raloxifene Enrolls 6,000 In First Year; 5 Percent Are Minorities

This article is from The Cancer Letter archive.

Vol. 23 No. 7 | July 28, 2000

Download PDF Visit The Full Archive

Related Articles

Cancer Control Program Guidelines Developed For Payment Of Patient Costs

December 21, 1973

ACS Says 41 Percent Survive 5 Years

January 2, 1981

The Clinical Trials Working Group: NCI panel considers plan to centralize clinical trial review and prioritization. NCI director faults system for duplication, “equivocal results.”

August 13, 2004

Phase III Trial Data: Lenvatinib Extends PFS by Over 14 Months

June 27, 2014

DCCPT Board, NCAB Approve Core Grant Guideline Changes, Consortium Centers

May 17, 1985

In Brief; “Sense of Urgency” In Research Is Theme of New AACR President Daniel Von Hoff

April 16, 1999